Overweight & Obesity
Popularity of Ozempic and Wegovy among privately insured patients may worsen disparities, suggests study
A USC study suggests that publicly insured individuals who are most likely to benefit from new drugs for diabetes and obesity are less likely to get them than those with private insurance.
Aug 2, 2024
0
17